Browsing by Author "Ashutosh Tiwari"

Now showing 1 - 4 of 4

Acute Cardiac Events After ChAdOx1 nCoV-19 Corona Virus Vaccine: Report of Three Cases
(Lippincott Williams and Wilkins, 2022) Rohit Singh; Sankha Shubhra Chakrabarti; Indrajeet Singh Gambhir; Ashish Verma; Ishan Kumar; Soumik Ghosh; Ashutosh Tiwari; Gourav Chandan; Sasanka Chakrabarti; Upinder Kaur
[No abstract available]
Disseminated neurocysticercosis: Stars beyond the sky
(BMJ Publishing Group, 2015) Rameshwar Nath Chaurasia; Ashutosh Tiwari
[No abstract available]
Hyper-Eosinophilic Syndrome with Myocarditis after Inactivated SARS-CoV-2 Vaccination-A Case Study
(Bentham Science Publishers, 2023) Ashutosh Tiwari; Gaurav Karna; Sankha Shubhra Chakrabarti; Prasan Kumar Panda; Upinder Kaur
Introduction: COVID-19 vaccine-induced serious adverse reactions are rare. Hyper-eosinophilia syndrome with myocarditis has not been reported earlier following BBV152 vaccine administration. Case Presentation: A young man without any co-morbidities presented with persistent periorbital swelling along with itchy swelling over fingers, resting tachycardia, and exertional breathlessness following the first dose of an inactivated SARS-CoV-2 vaccine (BBV152, COVAXIN). On inves-tigation, the patient had elevated blood eosinophils (maximum 21.5% with an absolute eosinophil count of 2767/mm3) and myocarditis (Lake Louise Criteria). He was successfully treated with ster-oids and supportive treatment. Conclusion: This is the first reported case of hyper-eosinophilia syndrome after COVAXIN ad-ministration. Prior history of the allergic disease may be a predisposing factor in this case. Hyper-eosinophilia can present with variable symptoms. In the current case, myocarditis was present with persistent resting tachycardia and dyspnea. Steroid and antiallergic drugs may be successful for the treatment of vaccine-induced hyper-eosinophilia with myocarditis. Increased vigilance is needed for such adverse events. © 2023 Bentham Science Publishers.
Lecanemab: More Questions Than Answers!
(Adis, 2024) Upinder Kaur; Jaideep Reddy; Ashutosh Tiwari; Sasanka Chakrabarti; Sankha Shubhra Chakrabarti
The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer’s disease. Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer’s disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase III trials. However, there have been many questions raised over the clinical relevance of the otherwise minimal cognitive improvements. Furthermore, its rapid approval has been mired in controversy, in addition to the reports of adverse events such as amyloid-related imaging abnormalities and several deaths of participants in the lecanemab trials. Here, we analyze the evidence supporting lecanemab as an amyloid beta therapy and also discuss the concerns raised about its efficacy and safety. © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.